Last reviewed · How we verify
NCT07302230: EMPOWER
Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Among Patients With Non-muscle Invasive Bladder Cancer, The EMPOWER Trial
NA trial testing Internet-Based Intervention in Localized Non-Muscle Invasive Bladder Urothelial Carcinoma in 100 participants. Currently enrolling.
26 February 2027
Quick facts
| Lead sponsor | University of Washington |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 100 |
| Start date | 11 March 2026 |
| Primary completion | 26 February 2027 |
| Estimated completion | 31 May 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Internet-Based Intervention
- Best Practice
- Internet-Based Intervention
- Exercise Intervention
- Health Telemonitoring
- Educational Intervention
- Questionnaire Administration
- Interview
- Electronic Health Record Review
Conditions studied
- Localized Non-Muscle Invasive Bladder Urothelial Carcinoma — all drugs for Localized Non-Muscle Invasive Bladder Urothelial Carcinoma →
- Stage 0a Bladder Cancer AJCC v8 — all drugs for Stage 0a Bladder Cancer AJCC v8 →
- Stage 0is Bladder Cancer AJCC v8 — all drugs for Stage 0is Bladder Cancer AJCC v8 →
- Stage I Bladder Cancer AJCC v8 — all drugs for Stage I Bladder Cancer AJCC v8 →
Sponsor
University of Washington
Who can join
18 and older, any sex, with Localized Non-Muscle Invasive Bladder Urothelial Carcinoma or Stage 0a Bladder Cancer AJCC v8. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial compares how well a home-based personalized physical activity program (PAP) that is delivered by a digital application (app) (the ExerciseRx app) works compared to health education in improving physical activity for patients with bladder cancer that has not reached the muscle wall of the bladder (non-muscle invasive). For people who are not physically active, previous studies have shown that increasing step counts can reduce incidence of death, reduce frailty, and reduce healthcare costs. The ExerciseRx app tracks adherence to home exercise, adapts step count goals based on the patient's progress, and provides encouraging feedback and motivation from the healthcare team. Additional features include activity summaries, progress towards current goal, nudges, helpful facts about the benefits of activity, and ideas for how to incorporate daily movement. A home-based PAP using the ExerciseRx app may work better in increasing physical activity among patients with non-muscle invasive bladder cancer compared to a health education only group.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07302230
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Internet-Based Intervention
Trials testing the same drug.
- NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
- NCT05874297 — Online Nutrition Education to Decrease the Side Effects of Chemotherapy in Patients With Breast Cancer · NA · not yet recruiting
- NCT07439484 — Individually Tailored, Supervised, Remote Exercise Intervention to Improve Physical Function for Stage I-III Gastroesoph · NA · not yet recruiting
- NCT07202247 — Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabol · Phase 2 · recruiting
- NCT07225920 — Understanding Needs of Older Patients Prior to Starting Cancer Treatment · NA · enrolling by invitation
Other University of Washington trials
Trials by the same sponsor.
- NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
- NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
- NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
- NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
- NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07302230 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Washington
- Last refreshed: 13 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07302230.